Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oragenics Inc OGEN

Healthcare Biotechnology
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.


NYSEAM:OGEN - Post by User

Oragenics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(302)
•••
Post by whytestockson Aug 19, 2024 7:00pm
48 Views
Post# 36186905

BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Repo

BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Repo
Breaking News: $OGEN BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion2024-08-19 10:44:57 ET Oragenics (NYSE American: OGEN) , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has released a business status update. According to the update, which outlines key 2024 progress, the company cont...OGEN - BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities